1. Bucala R, et al. Mol Med 1994; 1(1): 71-81.
2. Mori L, et al. Exp Cell Res 2005; 304(1): 81-90.
3. Bianchetti L, et al. J Cell Mol Med 2012; 16(3): 483-495.
4. Kao HK, et al. Ann Surg 2011: 254(6): 1066-1074.
5. Geiger A, et al. Biochem Biophys Res Commun 2015; 467(2): 303-309.
6. Ling C, et al. Sci Adv 2019; 5: eaav7384.
7. Li B, et al. Front Cardiovasc Med 2021; 8: 753711.
Announcement of October 10, 2022
Generation and Drug Delivery Properties of Engineered Exosomes Homing to the Lung
The Avail Biomedical Research Institute has successfully generated engineered exosomes for the targeted delivery of biologics to the alveolar capillaries of the lung. It has now started the preclinical studies that are required to determine the shelf life, biodistribution and toxicological profile of the intravenously injected clinical-grade exosomes targeting forms of progressive pulmonary fibroses for which there are few, scarcely effective, therapeutic options and no cure.